Semler Scientific, founded with a mission to innovate diagnostic products for patient risk-assessment, aims to transform healthcare by supporting the early detection and monitoring of chronic diseases such as Peripheral Arterial Disease (PAD). The company develops, manufactures, and markets diagnostic and testing products that help healthcare providers identify patients' risk profiles, thereby optimizing their ability to capture full reimbursement potential for their services. Semler Scientific primarily focuses on the U.S. market.

Notable affiliated people and investors include industry experts and venture capital firms specializing in medical technology. Semler Scientific has achieved significant milestones, including the successful development and commercialization of its diagnostic tools. The company's impact is evident in its contribution to improving early disease detection and enhancing healthcare providers' operational efficiencies, ultimately leading to better patient outcomes and optimized healthcare reimbursements.